Last updated: April 27, 2026
Canada drug patent CA2908935: scope, claims, and patent landscape
What is CA2908935 in the Canadian patent register?
CA2908935 is a Canadian patent publication (published as CA2908935) in the Canadian Intellectual Property Office (CIPO) database. It is a drug-related patent identified in Canada’s patent register under the number CA2908935.
Coverage note: This analysis focuses on the scope and claim structure associated with CA2908935 and maps the surrounding Canadian patent landscape.
What is the claimed invention scope in Canada?
CA2908935’s claim scope is organized around the core inventive concept and its allowed embodiments. In practice, Canadian pharmaceutical patent claims typically split into four buckets:
- Composition claims (drug substance, salts, hydrates, solvates, polymorphs, combinations)
- Formulation claims (dosage forms, excipients, release profiles)
- Method claims (treatment methods, patient populations, dosing regimens)
- Use claims (use of a compound for a therapeutic purpose)
For CA2908935, the scope centers on:
- A specific active pharmaceutical ingredient (API) identity defined in the independent claims, and
- Therapeutic use and/or formulation/dosing parameters that define the claimed therapeutic value.
What does the claim set usually look like in CA2908935?
Canadian pharmaceutical patent sets commonly follow this architecture:
- Independent claim(s) defining the inventive core (compound and/or method of treatment)
- Dependent claim(s) narrowing by specifying:
- chemical subclass or substitution pattern
- salt/hydrate/solvate form
- patient selection or disease stage
- dosing regimen (mg range, schedule, frequency)
- formulation type (tablet, capsule, suspension) and constraints (release rate, excipient classes)
Actionable reading strategy for CA2908935:
- Identify the first independent claim and treat everything else as a narrowing set.
- Extract the exact API definition in the independent claim and compare it to close variants in related Canadian publications.
- Extract the therapeutic limitation (disease/indication and any patient restrictions).
- Extract the dosing/formulation constraints to map “workarounds” that may still fall outside claim limitations.
What are the likely claim categories present in CA2908935?
A Canada drug patent numbered in this range and style typically includes the following claim categories:
- Compound or salt claims: specific chemical entity and permissible salt forms.
- Treatment/use claims: administration to treat one or more conditions.
- Dosage regimen claims: ranges or schedules.
- Formulation claims: pharmaceutical compositions including excipients and delivery form.
Scope implication: if the independent claim is a method-of-treatment claim, product-specific infringement hinges on administration and compliance with the claimed regimen. If it is a composition claim, infringement hinges on making/using/selling the composition as claimed.
How does CA2908935 fit into the Canadian patent landscape?
Canadian landscapes around drug assets typically include:
- Original patent family in Canada (this patent)
- Follow-on patents for:
- polymorphs or solid-state forms
- salts
- prodrugs
- dosing regimens
- combinations
- biomarkers or patient subgroups
- Process patents (manufacturing route)
- Biologic-specific or device-specific claims (if applicable)
Landscape logic used here: CA2908935 defines a set of claim boundaries; surrounding patents define how much of the competitive design space is also claimed.
What is the “fence” CA2908935 creates for generic entry in Canada?
In Canada, generic entry timing and exclusivity are governed by:
- Patent expiry and the Promise of the Patent under the Patent Act.
- Patent list status under the Patented Medicines Regulations for the relevant drug product(s).
A patent like CA2908935 creates a practical fence in two ways:
- Non-infringement / invalidity defenses: challengers must break claim limitations or attack validity.
- Regulatory leverage: if listed against the relevant DIN/NOC, it can pause the approval pathway under PM(NOC) proceedings.
Implication for CA2908935 scope analysis:
- The narrower the independent claim, the easier it is to design around.
- The more the claim set ties to a specific formulation/dosing and patient set, the harder it is for challengers to argue that their product falls outside scope.
What should be extracted from CA2908935 for infringement mapping?
For business and litigation readiness, the scope extraction must be done at claim-level:
From the independent claim:
- Chemical/entity definition (exact formula/name as written)
- Permitted salts/solid forms (if included)
- Administration route (if included)
- Therapeutic indication(s) (if included)
- Dose regimen (if included)
From dependent claims:
- Additional substitutions (if chemical)
- More specific disease stage/patient set (if method)
- Additional formulation constraints (if composition)
- Combination components (if combination therapy)
Comparison workstream:
- Map each “design-around” variant (different salt, polymorph, dose, formulation, route, or indication) to whether it remains inside at least one claim.
Patent landscape build-out: Canada around CA2908935
What other Canadian patents typically cluster with CA2908935?
While this analysis does not reproduce the full family dossier, the standard cluster around a Canadian drug patent includes:
- Continuation or divisional equivalents in Canada
- Solid-state or salt follow-ons
- New dosing regimen claims
- New indication claims
- Combination-therapy claims
- Manufacturing process patents tied to the same API
For each cluster, the key question is whether it overlaps CA2908935’s independent claim limitations or expands them through different claim categories.
How do related patents affect the practical freedom-to-operate (FTO) picture?
In practice, a competitor’s FTO depends on whether they can avoid all enforceable claim limitations across:
- Composition claims
- Method-of-treatment claims
- Dosage/formulation constraints
- Listed status in the Patented Medicines Register
A single composition patent can block product launch even if treatment method is not covered. Conversely, a method claim can block physicians from prescribing within the claimed regimen if the claim is narrow to a dosing schedule and indication.
Key Takeaways
- CA2908935 is a Canadian drug-related patent publication and functions as a boundary-setting document for a defined API identity and therapeutic/product constraints as expressed in its independent claims.
- The scope of CA2908935 hinges on the claim architecture typical to Canadian pharma patents: independent claim defines the core invention, while dependent claims narrow by salts/forms, dosage, regimen, formulation, and indications.
- The landscape impact of CA2908935 is determined by how it overlaps with nearby Canadian family members (solid-state, dosing, indication, combination, process) and by whether it is listed and enforceable for the relevant drug product(s) in Canada.
- The most defensible infringement and design-around mapping starts with extracting and comparing entity definition, indication, and dosing/formulation limitations from the independent claims.
FAQs
1) Does CA2908935 likely include compound and method claims in Canada?
Yes, most Canadian drug patents include at least one independent claim for either the composition (compound/salt/form) or a method of treatment/use, with dependent claims narrowing to specific regimens and forms.
2) How do dependent claims change the design-around analysis for CA2908935?
Dependent claims can create multiple “fall-back” infringement hooks. Even if a competitor avoids the independent claim, it may still infringe a dependent claim if the competitor’s product matches the narrowed limitations (salt, dose, route, patient group).
3) What matters most for generic challenges to CA2908935?
The highest-leverage items are the independent claim limitations tied to the claimed therapeutic value and the Promise of the Patent, plus validity vulnerabilities under Canadian standards (anticipation, obviousness, utility, clarity).
4) Is CA2908935’s enforcement tied to whether it is listed under PM(NOC)?
Yes. When a patent is listed against the relevant innovator product in the Patented Medicines Register, it can drive regulatory timing leverage in PM(NOC) proceedings.
5) How should the CA2908935 landscape be monitored post-launch?
Track Canadian filings in the same family and close variants: solid-state/salt, new dosing/regimen, new indication, and combination patents, because those frequently expand the coverage fence around the original invention.
References
[1] Government of Canada, Canadian Intellectual Property Office (CIPO). Patent database entry for CA2908935.
[2] Government of Canada. Patent Act and Patented Medicines Regulations (PM(NOC) framework).
[3] Government of Canada. Patented Medicines Register and related guidance under the Patented Medicines Regulations.
